{
    "pmcid": "8956255",
    "qa_pairs": {
        "What specific technique was used to map the binding sites of nanobodies on the RBD in the study?": [
            "Hydrogen/deuterium exchange mass spectrometry (HDX-MS)",
            "X-ray crystallography",
            "Cryo-electron microscopy",
            "Nuclear magnetic resonance (NMR) spectroscopy"
        ],
        "What was the primary focus for nanobody targeting on the SARS-CoV-2 spike protein?": [
            "Receptor Binding Domain (RBD)",
            "N-terminal Domain (NTD)",
            "S2 Subunit",
            "Fusion Peptide"
        ],
        "What was the therapeutic application explored for nanobodies in the study?": [
            "A half-life\u2013extended C7 construct (C7-Alb1) in a transgenic mouse model",
            "Intravenous administration of G6 in human trials",
            "Oral delivery of E11 in non-human primates",
            "Topical application of nanobody dimers in ferrets"
        ],
        "Which method was used to determine the binding kinetics of RBD-specific nanobodies?": [
            "Surface plasmon resonance (SPR)",
            "Isothermal titration calorimetry (ITC)",
            "Biolayer interferometry (BLI)",
            "Fluorescence resonance energy transfer (FRET)"
        ],
        "Which nanobodies demonstrated substantial cross-neutralization of SARS-CoV-1 according to the study?": [
            "G6 and E11",
            "C7 and E2",
            "A1 and B2",
            "D3 and F4"
        ]
    }
}